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Gene discovery in glioma in the context of 
molecular reclassification of tumors
Conventional classification of tumors, especially in terms of staging and grading is of 
immense importance for both prognostication as well as management strategies. 
However it is not a perfect system and there are many instances where tumor behaviour 
does not correspond to what is expected.  In addition, with the onset of targeted therapy, 
the identification of the distinct molecular target in a subset of tumors becomes a 
marker of tumor behaviour as well as a target of therapy.  This leads to the concept of 
molecular subclassification of tumors where molecular markers further refine and in 
some cases, alter conventional classification. We would be presenting this concept in 
relation to glial tumors, especially in the context of molecular markers discovered in 
our laboratory.
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Diagnosis and grading of gliomas :
 Malignant gliomas are one of the 
lethal central nervous system (CNS) 
cancers with high mortality rate. The 
molecular and genetic changes observed 
in the development and progression of 
gliomas are becoming better understood 
but are far from complete and many more 
molecular markers need to be identified 
and analyzed. For establishing a diagnosis 
of CNS cancers histologic examination of 
the biopsied tissue sample is the gold 
standard along with radiological analysis 
to highlight the location of the tumor as 
well as to correlate the clinical symptoms. 
 G l i o m a s  a r e  c l a s s i f i e d  
histologically, using the grading system 
mainly based on the St. Anne/Mayo 
criteria, on the basis of cell type and the 
degree of differentiation, into different 
grades like WHO (World Health 
Organization) grade-I, WHO grade-II and 
so on (1). On the basis of the origin of 
cells, WHO classifies gliomas into 
astrocytomas, oligodendrogliomas, 
e p e n d y m o m a s  a n d  m i x e d  
oligoastrocytomas  (1, 2).  And on the 
basis of the degree of cellular 
differentiation astrocytoma is graded into 
four WHO grades (WHO grade I-IV). 
WHO grading of astrocytomas is one of 
the most important prognostic factors in 
predicting patient outcome, with WHO 
grade-I having low proliferative potential 
and non progression to higher grades. 
They are more likely to be cured following 
surgery. Grade II exhibit marked potential 
for subsequent progression towards grade 
III and grade IV with fatal outcome (1). 
 The conventional mode of 
treatment is surgery followed by chemo- 
and radio-therapy, based on histological 
tumor grades. However, histological 
grading of gliomas can be difficult and 
subject to inter-observer variation (3 ) as 
well as influenced by the biases of treating 
physician and institutional practice 
patterns (4). With the advancement in the 
understanding of the tumor development 
and involvement of different oncoproteins 
a n d  t u m o r  s u p p r e s s o r s ,  
immunohistochemistry (IHC) has been 
e m p l o y e d  t o  i d e n t i f y  p r o t e i n s  
(immunomarkers) that are involved or 
affected in the process of tumorigenesis 
with implications in diagnosis and 
prognosis. For example, overexpression 
of p53 protein has been used to 
differentiate astrocytic tumors from 
oligodendrogliomas as well as to 
determine the histological grading of 
astrocytic tumors (5). Similarly, other 
proteins like EGFR, PDGFR, CD44, 
OLIG2 etc. have been demonstrated as 
biomarkers for diagnosis and prognosis of 
gliomas. 
 Molecular genetic analysis and 
gene expression profiling further helped 
in tumor subclassification and are found to 
correlate better with prognosis than 
histology. In glioma, the molecular tumor 
subgroups formed on the basis of 
differential gene expression have been 
found to associate with distinct patterns of 
genetic changes in terms of LOH (loss-of-
heterozygosity), gene amplification and 
mutations etc. Some of the well studied 
markers helping in the diagnosis and 
prognosis of gliomas are LOH of 1p/19q, 
loss of 17p and 10q, amplification of 
EGFR and mutations of IDH1/IDH2 etc. 
(3). Glioblastomas (WHO grade IV) are of 
t w o  t y p e s ,  d e  n o v o  ( p r i m a r y  
g l i o b l a s t o m a s )  a n d  s e c o n d a r y  
glioblastomas (progression from low-
grade gliomas). Primary glioblastomas 
develop in older patients and are 
characterized by EGFR overexpression, 
PTEN mutations, p16 deletions, and 
occasionally, MDM2 amplification 
whereas secondary glioblastomas develop 
in younger patients and typically have 
TP53 mutations(6). These subtypes 
constitute distinct molecular features that 
evolve via different genetic pathways and 
show different prognosis and response to 
therapy. 
 It is now increasingly apparent 
that epigenetic changes such as DNA 
methylation and histone modification 
affect gene expression in a significant way 
so as to affect cancer phenotype and 
treatment response (7). Hypermethylation 
is associated with heterochromatization 
and reduced target gene expression. In 
glioma hypermethylation of O(6) 
methylguanine-DNA methyltransferase 
(MGMT) gene promoter is an indicator of 
better response to temozolomide (TMZ) 
(8).  MGMT is a DNA repair enzyme 
(demethylating DNA bases) and protect 
cells from cell death. Temozolomide 
(TMZ) ki l ls  cel ls  by increased 
methylation of purine bases of DNA, 
hence, hypermethylated MGMT (low 
expression) is an indicator of better TMZ 
response (9). The 1p/19q co-deletion or 
MGMT methylation status are being 
implicated in clinical practice to stratify or 
select patients with diffuse glioma for 
further management. 
 Similarly, the recently discovered 
non coding RNAs which get processed 
into miRNAs are found to target mRNA 
sequences and induce their degradation or 
translational silencing. Role of miR-21 in 
down-regulating expression of tumor 
suppressor PDCD4 is well known in 
gliomas  (10) and other tumors (11, 12, 
13 ). The tumor suppressor p53 was found 
to be a positive regulator of miR-34a 
expression and miR-125b as a negative 
regulator of p53  (14, 15). These are few 
examples of the functional relationship 
between mRNA & miRNA and their role 
in tumor progression. These genetic and 
m o l e c u l a r  c h a n g e s  ( D N A /  
epigenetic/RNA) are being considered as 
biomarkers, helping in improved 
diagnostics,  prognostication and 
therapeutic outcomes. The hybrid 
terminology for the combination of 
diagnostics and therapy in a single 
molecule recently has been coined as 
'theranostics' (16). Use of these molecular 
markers in routine clinical practices has 
helped in grading and classifying gliomas 
in more objective manner than with the 
use of histology alone.  
 Another important marker type 
identified is the cancer stem cell (CSC) 
markers. They are considered to be  
important predictor of prognosis and 
recurrence of tumors but currently no CSC 
markers are in clinical use.  Recently, a 
study showed the significance of Nestin 
expression and its association with short 
progression-free survival (PFS) in WHO 
grade II tumors  (17).   
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Molecular markers predictive of tumor 
behaviour used in clinical practice :
 Molecular phenotyping is being 
increasingly used nowadays as a means of 
diagnosis as well as prognostication in 
glioma patients. Mutations in IDH1 occur 
mostly in patients with secondary GBMs 
and have been associated with an increase 
in overall survival (18). In primary GBM 
tumors, simultaneous mutations in p53 
and EGFR amplification were found to be 
significantly associated with worse 
survival (19). Methylation of DNA repair 
g e n e  O ( 6 ) - m e t h y l g u a n i n e - D N A 
methyltransferase (MGMT) promoter and 
high PTEN protein expression have been 
shown as favorable factors for prolonged 
survival in GBM patients treated with 
temozolomide (20, 21 ).  1p/19q co-
deletion has been shown to correlate with 
b e t t e r  o u t c o m e  i n  a n a p l a s t i c  
ol igoastrocytoma and anaplast ic  
oligodendroglioma patients  (22).  
Molecular subtyping of histologically 
similar tumors: TCGA Classification of 
tumors :
 Recently, there have been global 
efforts on the process of classifying 
tumors based on pooling of high 
throughput data from several centres.  A 
major initiative by the National Cancer 
Institute (NCI), the National Human 
Genome Research Institute (NHGRI), and 
27 institutes/centers of the National 
Institute of Health (NIH) have established 
the Cancer Genome Atlas (TCGA) 
Research Network (2008) which has 
generated a vast, comprehensive 
catalogue of genomic abnormalities 
underlying tumorigenesis in more than 20 
types of cancers (23, 24). With respect to 
GBM, the repository provides detailed 
genomic changes in a cohort containing 
over 500 patient  samples (25).  
Computational analyses of the TCGA data 
have identified four molecular subtype 
p r o f i l e s  o f  G B M :  C l a s s i c a l ,  
Mesenchymal, Proneural, and Neural; 
based on the expression of signature genes 
(23) .  The  Class ica l  subtype  i s  
characterized by EGFR amplification, 
homozygous deletion of Ink4a/ARF 
locus, and chromosome 7 amplifications 
and chromosome 10 deletions. The 
Mesenchymal subtype shows high 
frequency of NF1 mutation/deletion with 
low NF1 mRNA expression and high 
expression of CHI3L1 and MET. The 
Proneural subtype is associated with 
PDGFRA abnormalities and mutations in 
IDH1 and TP53, while the Neural subtype 
GBMs are confirmed by the expression of 
neuron markers like NEFL, GABRA1, 
SYT1 and SLC12A5. The gene 
expression signatures found in the Neural 
subtype are suggestive of neural, 
astrocytic and oligodendrocytic cellular 
phenotype. Although morphologically 
indistinguishable, these subtypes exhibit 
distinct molecular profiles, survival 
length as well as treatment response. 
 It is expected that this and similar 
approaches of combining high throughput 
analysis of tumor types will result in a 
molecular classification of tumors – as a 
further refinement of histological grading, 
that would enable prognostication and 
treatment strategies based on specific 
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molecular alterations in the tumors. 
Hence, there has been extensive research 
based on both high throughput as well as 
conventional analysis to identify 
molecular features that would predict 
behaviour as well as identify susceptible 
points in a tumor cell that could be used for 
individualized therapeutic intervention.
Experimental markers in diagnosis and 
therapy :
 Several genetic alterations define 
subclasses in GBM that describe differing 
diagnosis as well as response to targeted 
therapies. Coexpression of EGFR variant 
III and PTEN by GBM cells is associated 
with responsiveness to EGFR kinase 
inhibitors  (26). Another therapeutic 
inhibitor, bevacizumab, is an anti-VEGF-
A monoclonal antibody that targets the 
very hallmark of GBM pathogenesis, i.e. 
angiogenesis.  It received FDA's approval 
for recurrent glioblastoma in May 2009, 
based on the significant response rate and 
clinical benefits demonstrated by 
randomized phase II studies. A subsequent 
meta-analysis of 15 studies published 
from 2005 to 2009, involving 548 
patients, has shown similar efficacy 
benchmarks as those in the phase II 
studies  (27). 
 Recent reports also suggest 
miRNA expression profiles as more 
effective in tumor classification than 
protein-coding gene expression profiles. 
The advantages of miRNAs as biomarkers 
include a less extensive miRNA 
expression data (1000 miRNAs as 
opposed to >40,000 protein-coding 
genes). Further, miRNAs are less 
subjected to degradation and more easily 
retrieved from formalin-fixed, paraffin-
embedded tissues (28, 29, 30, 31 ). 
miRNA signatures have been identified as 
independent predictors for determining 
high risk of unfavorable outcome in GBM 
patients  (28). Li et al have analyzed 
miRNA signature in five subtypes 
[Classical, Mesenchymal, Neural, 
Proneural-CpG island methylator 
phenotype (G-CIMP) and Proneural-non 
G-CIMP] of GBM in the TCGA dataset 
 (32). They identified a prognostic miR 
signature in Mesenchymal subtype that 
may help in sub-stratification of the 
patients for personalized treatment and 
management. 
Our approaches to gene discovery in 
glioma markers :
 Our laboratory identified a novel 
gene 'FAT1' by employing RAPD (random 
amplification of polymorphic DNA)-PCR 
technique in astrocytic tumors of WHO 
grade II and IV  (33). RAPD-PCR is a 
locus non-selective DNA fingerprinting 
technique that detects alterations by 
scanning the entire genome. Scoring of 
alterations [loss/gain/change in the 
intensity of band(s)] is done by comparing 
the band pattern of tumor DNA with that 
of normal leucocytes DNA (Fig. 1a). 
Since the technique is not restricted to a 
defined locus, it enables identification of 
genomic regions that have not yet been 
published or have not been obvious 
immediately after analysis of sequences. 
With the use of RAPD primer 80/07, loss 
of a 500bp band was detected in 33% 
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Figure 1: (a) Representative RAPD gel profile showing alterations (arrows) in the 
form of loss/gain/change in intensity of band(s) in tumor (T) as compared to normal 
leucocyte DNA (B) of the same patient, with different primers (primer nos. 80/01, 
70/04, 70/01, 60/31). (b-i) RAPD gel profile of primer no. 80/07 indicating the 
frequent loss of a 500 bp band (arrow) in astrocytic tumors (T) as compared to the 
corresponding normal leucocyte DNA (B). (b-ii) Southern blot of the same RAPD 
profile, Southern hybridization was done to confirm the altered fragment with a 
radiolabeled probe prepared from 500 bp altered band eluted from the RAPD profile 
of normal DNA from another gel. (c) Amplification of normal (B) and tumor (T) 
DNA with loss of 500 bp band with specific primer pair designed to amplify the FAT 
gene corresponding to the altered band along with 100 bp on either side. Bands were 
eluted from the gel and sequenced to look for deletion(s)/mutation(s) at RAPD 
primer binding sites. M represents molecular marker (Source: Chosdol et al BMC 
Cancer 2009; Creative Commons Attribution License 4.0).
(4/12) of the grade II astrocytic tumors 
studied (Fig. 1b). The high frequency of 
the alteration suggested its association 
w i t h  t u m o r i g e n e s i s .  F u r t h e r  
characterization of the corresponding 
band in normal DNA was carried out by 
Southern hybridization, cloning and 
sequencing followed by BLAST search in 
the public domain genome database which 
showed 100% homology to FAT1 at 
exon2-intron2 junction on chromosome 
4q34-q35 locus. 
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Figure 2: Simultaneous knockdown of FAT1 and PDCD4 reverses the effects of 
FAT1 knockdown. (a) FAT1 and PDCD4 mRNA expression was analyzed by q–PCR 
in U87MG cells treated with siFAT1 and siPDCD4 alone, as well as both the siRNAs 
treated simultaneously. Treatment with siFAT1+siControl was found to upregulate 
PDCD4 expression, whereas treatment with siFAT1+siPDCD4 downregulated the 
PDCD4 expression to the level of siControl-treated cells alone. (b, c) Simultaneous 
knockdown of FAT1 and PDCD4 in U87MG cells restored their migratory and 
invasive properties comparable to that of siControl-treated cells. There was 
significant increase in cell migration and invasion in U87MG cells treated with 
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 Available literature on FAT1 
shows its dual role in human cancers. 
FAT1 has been demonstrated as an 
oncogene in breast carcinoma, leukemia 
and oral squamous cell carcinoma (34, 35, 
36).However, other reports have 
suggested its tumor suppressor role in oral 
cancer and Mayer-Rokitansky-Küster-
Hauser (MRKH) syndrome  (37, 38). 
 Initial report from our laboratory 
had shown LOH at FAT1 locus in 50% of 
grade II and IV astrocytic tumors (n=40) 
analyzed by microsatellite (intragenic) 
and by SNP markers; and low mRNA 
expression of FAT1 in glial tumors (9 
grade II and 9 grade IV tumors), implying 
the possibility of a tumor suppressive role 
(33). However, a functional analysis 
carr ied out  by s iRNA-mediated 
knockdown of FAT1 revealed its 
oncogenic role in glioma, whereby 
downregulation of FAT1 expression led to 
decrease in migration and invasion in 
GBM cell lines (39). Following FAT1 
k n o c k d o w n ,  i n c r e a s e d  P D C D 4  
(programmed cell death 4, a tumor 
suppressor gene) expression was seen to 
reduce phospho-c-Jun which is required 
for AP-1 transcriptional activity. Hence, 
decreased FAT1 expression diminished 
AP-1 dependent transcription of 
downstream genes like extra cellular 
matrix (ECM)-remodeling molecules 
(MMP3, PLAU and VEGF-C) and pro-
inflammatory markers (COX-2, IL1β and 
IL-6) (Fig. 2). This process was reversed 
by simultaneous knockdown of FAT1 and 
PDCD4, thereby, confirming the link 
between the two for regulation of cellular 
motility, invasiveness and inflammatory 
microenvironment in glioma (Fig. 2 & 
3). 
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siFAT1+siPDCD4 as compared with cells treated with siFAT1+siControl. Cells were 
counted in five different fields. Each value is mean±s.d. Experiment was put up in 
triplicate and repeated twice. (d) AP-1 luciferase activity significantly increased after 
PDCD4 knockdown in U87MGsiFAT1 cells. The luciferase activity with siControl is 
designated as 100%. There was a significant increase in AP-1 luciferase activity in 
U87MG cells treated with siFAT1+siPDCD4 as compared with siFAT1+siControl. 
And the luciferase activity in cells treated with siFAT1+siPDCD4 is comparable to 
siControl-treated cells. The experiment was repeated thrice following each of three 
independent transfections and representative data are shown. Results are expressed 
as mean±s.d. (e) The mRNA expression of AP-1-target genes increased in U87MG 
cells treated with siFAT1+siPDCD4 as compared with siFAT1+siControl. 18S was 
used as internal control and experiments were done in triplicate. (f) PDCD4 
knockdown in U87MGsiFAT1 cells revert back the protein expression of p-c-Jun, 
VEGF-C and COX-2 comparable to siControl-treated cells alone. Lysates from 
indicated cells were probed with respective antibodies. β-actin was used as control 
antibody (Source:  Dikshit et al Oncogene 2013; Creative Commons Attribution 3.0 
Unported License).
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 The mRNA expression of FAT1, 
PDCD4, COX-2 and IL-6 was analyzed in 
a set of 35 primary human GBM tumors 
and subjected to quartile analysis. The 
expression of PDCD4 was found to be 
inversely  correla ted with  FAT1 
expression, with a significant difference 
of PDCD4 expression (P=0.0145) across 
the highest and lowest FAT1 GBM 
quartiles (Table 1). Similar comparison of 
expression of COX-2 and IL-6 depicted 
their positive correlation with FAT1 
expression.   
 Essentially, the functional studies 
on the role of FAT1 in tumorigenesis are 
still very few. It is possible that FAT1 acts 
via different signaling cascades and 
cellular processes in different contexts 
wh ich  s t i l l  n eed  c l a r i f i c a t i on .  
Nevertheless, a pro-inflammatory 
environment plays a favourable role in 
tumor pathogenesis and has been 
discussed as one of the emerging 
hallmarks of solid tumors, including 
glioblastoma  (40). The study carried out 
by Dikshit et al highlights the importance 
of FAT1 in induction of expression of pro-
inflammatory molecules, apart from 
aiding cell migration and invasion in 
glioma. Our discovery of FAT1 as an 
oncogene in glioma makes it a prospective 
candidate for diagnosis and prognosis in 
future. 
Figure 3: The proposed signaling pathway downstream of FAT1 regulating AP-1-
dependent transcription. Knockdown of FAT1expression releases its inhibitory 
effect on PDCD4 and increase the expression of PDCD4. Increased PDCD4 
expression in turn inhibits the phosphorylation of c-Jun, thus decreasing phospho-c-
Jun levels. Because phospho-c-Jun is required for AP-1-dependent transcription, 
there was inhibition of AP-1 transcriptional activity and downregulation of target 
genes like COX-2, MMP3, VEGF-C, PLAU, IL-6 and IL-1b (Source: Dikshit et al 
Oncogene 2013; Creative Commons Attribution 3.0 Unported License). 
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Figure 4: A schematic diagram showing the variety of molecules used as biomarkers for 
purposes of diagnostics, prognostication and therapy. These are genes involved in cellular 
processes like apoptosis, cell cycle, DNA repair, signal transduction, cell invasion and 
metastasis; and undergo genetic changes at DNA or RNA level (eg. mutation, deletion/LOH, 
amplification, translocation, overexpression, variation in splicing, etc.) or epigenetic 
changes (eg. DNA methylation and histone modification). In our case, the use of 
bioinformatics approaches has led to the discovery of FAT1 gene in glioma as an oncogene 
which is a prospective candidate as a prognostic or diagnostic marker. It will also aid further 
identification of related molecules in the downstream signaling pathway as points of 
therapeutic intervention in patients. 
 The interesting concept about 
FAT1 is that its overexpression identifies a 
subset of human glioblastoma which have 
a high degree of proinflammatory 
cytokines and COX-2 expression. Hence 
it too may have a place as a “theranostic” 
–identifying a subset of tumors as well as 
suggesting (e.g. through agonist of COX-
2 and IL6), a means for therapeutic 
i n t e r v e n t i o n .  T h e s e  t u m o r s  
overexpressing FAT1 have very similar 
histological features as to those that do not 
overexpress the gene. This is a form of 
molecular subclassification within the 
same histological grade that we are now 
trying to establish further.
 The overall progress in the 
identification and application of 
m o l e c u l a r  m a r k e r s  i n  g l i o m a  
classifications and sub-classifications 
have tremendously been improved over 
the decades due to intense clinical 
research, improved bioinformatics and 
innovative research techniques being 
developed. Figure 4 schematically 
summarized the overall progress in the 
glioma diagnosis, prediction of prognosis 
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Table 1: Expression analysis of FAT1, PDCD4, COX-2 
and IL-6 in human GBM samples by q-PCR
Group Samples FAT1/
18S
PDCD4/
18S
COX-2/
18S
IL-6/
18S
Group A GBM10
GBM35
GBM11
GBM8
GBM24
GBM30
GBM25
GBM6
GBM5
70.560
34.844
19.990
19.490
13.990
13.707
8.138
5.980
5.290
3.160
0.774
0.438
0.430
0.004
0.056
0.002
0.303
0.112
1.765
6.821
8.168
1.905
2.346
0.006
0.387
14.929
0.337
80.171
18.189
5.152
0.020
3.238
0.067
1.597
12.862
1.834
Group B
GBM1
GBM23
GBM21
GBM34
GBM4
GBM13
GBM3
GBM22
0.034
0.007
0.006
0.006
0.003
0.003
0.002
0.002
0.000
0.003
0.001
0.002
0.000
0.000
0.000
0.002
0.014
0.002
0.001
0.010
0.007
0.702
0.611
0.010
1.279
0.003
74.028
73.262
3.494
4.332
3.399
0.081
GBM12
GBM7
GBM31
GBM33
GBM2
GBM32
GBM29
GBM28
GBM27
4.700
4.660
4.000
3.949
2.479
1.548
1.500
1.300
1.200
0.555
10.754
0.176
0.290
0.100
0.195
134.809
1.372
0.333
0.742
1.778
0.056
0.143
0.100
0.158
0.001
0.001
1.892
25.020
4.302
0.034
0.155
0.372
0.509
3.340
0.963
2.514
Group C
GBM9
GBM14
GBM15
GBM16
GBM17
GBM18
GBM19
GBM20
GBM26
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.000
0.000
0.000
43.633
40.818
106.912
82.124
69.487
143.998
1.347
0.030
0.004
0.120
0.058
0.743
0.009
0.140
0.288
0.232
8.545
0.838
0.041
0.007
0.226
0.004
0.009
0.017
Group D
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and finally for the personalised therapy. It 
is necessary to fully understand the 
“omics” signatures of each glioma patient 
that may further help in development of 
individualized management plan that may 
lead to complete disease cure or at least aid 
the conversion of a lethal cancer to a 
chronic disease.
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